Pepper Hamilton Life Sciences Speaker Series, 'To Disclose or Not: The FDA, the SEC and Life Science' (Gladwyn)
Heightened scrutiny of SEC disclosures regarding the drug development process has left some life science companies and their executives in the cross hairs of the SEC and shareholders. In a March, 2015 speech, the SEC’s Enforcement Director stated “[a]ccuracy of reporting in your dealings with the FDA is critical to getting investors the information they need. FDA dealings and approvals are the lifeblood of your business and are so important to investment decisions.”
Join Pepper attorneys
Scott R. Jones, Aline Fairweather,
Judith L. O’Grady and Gay Parks Rainville as they discuss the recent uptick in SEC enforcement actions and shareholder lawsuits premised on misrepresentations or omissions regarding the drug development process and the specific types of disclosures that are garnering heightened scrutiny.
This seminar is approved for one substantive CLE credit in Pennsylvania. Attorneys licensed in New Jersey may claim credit for this program under New Jersey's reciprocity policy.